Health care resource utilization and costs of patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapies across different settings of care: A real-world data analysis
{{output}}
Background: Chimeric antigen receptor T-cell (CAR T) therapies have transformed the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Receiving CAR T infusion in the hospital may be limited by constrained c... ...
